|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Radiant Research |
|---|---|
| Information provided by: | Radiant Research |
| ClinicalTrials.gov Identifier: | NCT00701727 |
Purpose
This is a prospective, placebo-controlled, cross-over trial comparing the the effects of approximately 7 weeks of placebo treatment to 7 weeks of ezetimibe (10mg/day) treatment on several parameters of RCT in men and post-menopausal women diagnosed with hypercholesterolemia. The primary hypothesis is that the ezetimibe treatment will increase the excretion of endogenous (plasma-derived) cholesterol as fecal sterols, with secondary hypotheses that there will be a significant increase in de novo cholesterol synthesis, treatment will increase cholesterol efflux from tissues into the bloodstream, and increase global RCT.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypercholesterolemia |
Drug: ezetimibe Drug: Placebo |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Placebo Control, Crossover Assignment, Efficacy Study |
| Official Title: | Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study |
| Estimated Enrollment: | 30 |
| Study Start Date: | June 2008 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
ezetimibe (10mg/day)for 7 weeks
|
Drug: ezetimibe
1 tablet,10mg, once a day, for 7 weeks
|
|
2: Placebo Comparator
Placebo control
|
Drug: Placebo
1 tablet, once a day, for 7 weeks
|
The study will compare the effects of approximately 7 weeks of placebo treatment to 7 weeks of ezetimibe (10mg/day) on: 1) the efficiency of endogenous (plasma-derived) cholesterol excretion (%/day) 2) de novo cholesterol (DNC) synthesis ((%/day) 3) cholesterol efflux from tissues into blood (Ra), and 4) global RCT (efflux from tissues that is excreted as fecal sterols). Subjects will receive 7 weeks of either treatment or placebo, undergo RCT and DNC measurements, taking 10 days, then cross-over to the alternate placebo or treatment for an additional 7 weeks, followed by a second set of RCT and DNC measurements.
Eligibility| Ages Eligible for Study: | 21 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | Radiant Research ( Michael H. Davidson, MD, FACC ) |
| Study ID Numbers: | Ezetimibe RCT-001 |
| Study First Received: | June 17, 2008 |
| Last Updated: | October 8, 2009 |
| ClinicalTrials.gov Identifier: | NCT00701727 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
metabolic diseases metabolic disorder dyslipidemias lipid metabolism disorders |
|
Antimetabolites Metabolic Diseases Hyperlipidemias Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Ezetimibe Anticholesteremic Agents Hypercholesterolemia Pharmacologic Actions Dyslipidemias Lipid Metabolism Disorders |